For the second quarter of 2021 (end-June 30, 2021), revenue was $19.3 million. Revenue was $10.6 million in the second quarter of 2020. Revenue for the first half of 2021 was $37.9 million, which is a 56% increase over the first half of 2020, according to the company.

Berkeley Lights reported a gross profit of $12.7 million in the second quarter of 2021 compared to $6.9 million during the same period in 2020.

The company also launched a subscription model, TechAccess, which expands customer access to the company platform. Also, the company expanded the installed base to 92 platforms, with seven new direct placements shipped in the second quarter.

Berkeley Lights expects 2021 revenue to total $90 million to $100 million, which would represent 40% to 56% increase from 2020.

Leveraging optofluidics to make therapeutic antibody discovery easier
The need for speed and accuracy in the development of therapeutic antibodies has prompted Berkeley Lights to upgrade its optofluidic tools to help customers...

Abveris expands antibody discovery offerings with second Beacon system
Abveris has starting using a second Berkeley Lights Beacon optofluidic system to enable expansion of its antibody discovery offerings.

Berkeley Lights offers new assays to aid cell line development
Berkeley Lights has launched Opto Assure, a series of assays that provides yield and product quality data during the early stages of cell line development.

Berkeley Lights launches Opto Plasma B Discovery 4.0 workflow
Berkeley Lights has launched its Opto Plasma B Discovery 4.0 workflow for antibody discovery which can advance from B cells to lead molecules in one week.